Prion protein self-interaction in prion disease therapy approaches

被引:1
|
作者
Rigter, Alan [1 ]
Priem, Jan [1 ]
Langeveld, Jan P. M. [1 ]
Bossers, Alex [1 ]
机构
[1] Cent Vet Inst Wageningen UR, Dept Infect Biol, Lelystad, Netherlands
关键词
prion protein; prion; conversion; binding domains; self-interaction; prion disease therapy; CREUTZFELDT-JAKOB-DISEASE; IN-VITRO CONVERSION; SUSCEPTIBILITY-LINKED POLYMORPHISMS; BOVINE SPONGIFORM ENCEPHALOPATHY; NATURAL SCRAPIE; INSERT MUTATION; CELL-CULTURES; PRP GENOTYPES; CLOSED FLOCK; PRNP GENE;
D O I
10.1080/01652176.2011.604976
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Transmissible spongiform encephalopathies (TSEs) or prion diseases are unique disorders that are not caused by infectious micro-organisms (bacteria or fungi), viruses or parasites, but rather seem to be the result of an infectious protein. TSEs are comprised of fatal neurodegenerative disorders affecting both human and animals. Prion diseases cause sponge-like degeneration of neuronal tissue and include (among others) Creutzfeldt-Jacob disease in humans, bovine spongiform encephalopathy (BSE) in cattle and scrapie in sheep. TSEs are characterized by the formation and accumulation of transmissible (infectious) disease-associated protease-resistant prion protein (PrPSc), mainly in tissues of the central nervous system. The exact molecular processes behind the conversion of PrPC into PrPSc are not clearly understood. Correlations between prion protein polymorphisms and disease have been found, however in what way these polymorphisms influence the conversion processes remains an enigma; is stabilization or destabilization of the prion protein the basis for a higher conversion propensity? Apart from the disease-associated polymorphisms of the prion protein, the molecular processes underlying conversion are not understood. There are some notions as to which regions of the prion protein are involved in refolding of PrPC into PrPSc and where the most drastic structural changes take place. Direct interactions between PrPC molecules and/or PrPSc are likely at the basis of conversion, however which specific amino acid domains are involved and to what extent these domains contribute to conversion resistance/sensitivity of the prion protein or the species barrier is still unknown.
引用
收藏
页码:115 / 128
页数:14
相关论文
共 50 条
  • [1] Prion protein disease and neuropathology of prion disease
    du Plessis, Daniel G.
    NEUROIMAGING CLINICS OF NORTH AMERICA, 2008, 18 (01) : 163 - +
  • [2] Prion protein and prion disease at a glance
    Zhu, Caihong
    Aguzzi, Adriano
    JOURNAL OF CELL SCIENCE, 2021, 134 (17)
  • [3] Approaches to therapy in prion diseases
    Tagliavini, F.
    BRAIN PATHOLOGY, 2014, 24 : 16 - 16
  • [4] Approaches to therapy of prion diseases
    Weissmann, C
    Aguzzi, A
    ANNUAL REVIEW OF MEDICINE, 2005, 56 : 321 - 344
  • [5] Potential approaches for heterologous prion protein treatment of prion diseases
    Seelig, Davis M.
    Goodman, Patricia A.
    Skinner, Pamela J.
    PRION, 2016, 10 (01) : 18 - 24
  • [6] Therapeutic approaches in prion disease
    Hachiya, NS
    Sakasegawa, Y
    Kaneko, K
    JOURNAL OF HEALTH SCIENCE, 2003, 49 (04) : 267 - 272
  • [7] Prion protein interaction with nucleic acids: Possible models for prion diseases and prion function
    Grossman, A
    Zeiler, B
    Adler, V
    Kryukov, V
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S71 - S71
  • [8] Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints
    Minikel, Eric Vallabh
    Zhao, Hien T.
    Le, Jason
    O'Moore, Jill
    Pitstick, Rose
    Graffam, Samantha
    Carlson, George A.
    Kavanaugh, Michael P.
    Kriz, Jasna
    Kim, Jae Beom
    Ma, Jiyan
    Wille, Holger
    Aiken, Judd
    McKenzie, Deborah
    Doh-Ura, Katsumi
    Beck, Matthew
    O'Keefe, Rhonda
    Stathopoulos, Jacquelyn
    Caron, Tyler
    Schreiber, Stuart L.
    Carroll, Jeffrey B.
    Kordasiewicz, Holly B.
    Cabin, Deborah E.
    Vallabh, Sonia M.
    NUCLEIC ACIDS RESEARCH, 2020, 48 (19) : 10615 - 10631
  • [9] Perspectives on prion biology, prion disease pathogenesis, and pharmacologic approaches to treatment
    DeArmond, SJ
    Prusiner, SB
    CLINICS IN LABORATORY MEDICINE, 2003, 23 (01) : 1 - +
  • [10] Prion Protein Interactions with Nucleic Acid: Possible Models for Prion Disease and Prion Function
    Abraham Grossman
    Brian Zeiler
    Victor Sapirstein
    Neurochemical Research, 2003, 28 : 955 - 963